Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase II study

Table 4 Studies investigating hyperfractionated accelerated radiotherapy regimen for locally advanced rectal cancer

Study	Number of patients	Design	Follow-up (mo)	Total RT dose	Intervals (wk)	Concomitant chemotherapy	pCR1	Local control	Down-staging
Coucke et al[24] 2006	250	Prospective	39 mo	41.6 Gy/1.6 Gy	1 wk	None	1.20%	91.70%	38%
Ceelen et al[22] 2007	50 vs 91	Prospective	67 mo vs 28 mo	41.6 Gy/1.6 Gy vs 45 Gy/1.8 Gy	13 d vs 6 wk	None vs 5-FU bolus chemotherapy	4% vs 18%	94% vs 95.6%	30% vs 51%
Voelter et al[23] 2006	33	Prospective	104 mo	41.6 Gy/1.6 Gy	1wk	CPT-11	NA	100%	33%
Brooks et al[42] 2006	20	Prospective	31 mo	25 Gy/1.67 Gy (CHART)	1 wk	None	NA	95%	NA
Widder et al[43] 2005	184	Prospective	43 mo	25 Gy/2.5 Gy	1 wk	None	NA	97.90%	NA
Bouzourene et al[29] 2003	104	Prospective	40 mo	41.6 Gy/1.6 Gy	1 wk	None	0%	92.30%	43%
Marsh et al[26] 2010	17	Prospective	NA	50.4-55.2 Gy/1.2 Gy	4-6 wk	Capesitabine 825 mg/m2-twice per day	18.80%	NA	81.25%
The present study	30	Prospective	60 mo	42 Gy/1.5 Gy	6-8 wk	5-FU (325 mg/m2) continuous infusion	21%	96.70%	59%

¹Pathological complete response; NA: Not available; RT: Radiotherapy; pCR: Pathological complete response.